Compare · ACHV vs IDXX
ACHV vs IDXX
Side-by-side comparison of Achieve Life Sciences Inc. (ACHV) and IDEXX Laboratories Inc. (IDXX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACHV and IDXX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- IDXX is the larger of the two at $43.11B, about 60.1x ACHV ($717.2M).
- ACHV has been more active in the news (9 items in the past 4 weeks vs 4 for IDXX).
- IDXX has more recent analyst coverage (25 ratings vs 11 for ACHV).
- Company
- Achieve Life Sciences Inc.
- IDEXX Laboratories Inc.
- Price
- $6.38-8.67%
- $560.52+2.44%
- Market cap
- $717.2M
- $43.11B
- 1M return
- -19.56%
- -
- 1Y return
- +51.79%
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1991
- News (4w)
- 9
- 4
- Recent ratings
- 11
- 25
Achieve Life Sciences Inc.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
IDEXX Laboratories Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Latest ACHV
- Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
- Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications
- SEC Form 4 filed by Achieve Life Sciences Inc.
- SEC Form 3 filed by Achieve Life Sciences Inc.
- Achieve Life Sciences Announces Granting of New Hire Inducement Awards
- Achieve Life Sciences Inc. filed SEC Form 8-K: Leadership Update
- Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer
- Stifel initiated coverage on Achieve Life Sciences with a new price target
- Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026
- Achieve Life Sciences Announced Granting of New Hire Inducement Awards
Latest IDXX
- Goldman initiated coverage on IDEXX Labs with a new price target
- KeyBanc Capital Markets initiated coverage on IDEXX Labs
- IDEXX Laboratories to Release 2026 Third Quarter Financial Results
- Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories
- IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection
- IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
- Director Kingsley Lawrence D exercised 2,203 shares at a strike of $114.17 and sold $1,172,178 worth of shares (2,203 units at $532.08) (SEC Form 4)
- IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
- EVP, CFO and Treasurer Emerson Andrew exercised 265 shares at a strike of $178.26 and covered exercise/tax liability with 86 shares, increasing direct ownership by 4% to 4,421 units (SEC Form 4)
- IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test